Denteric is developing a novel therapy called GPV381 for chronic inflammation. Initially treating periodontitis in patients with severe or refractory disease, GPV381 targets the toxins of a bacterium called Porphyromonas gingivalis.
The toxins are called gingipains and they drive inflammation damaging surrounding tissues, for example, the gums, ligaments and bone that support the teeth. GPV381 inhibits the gingipains, resulting in resolution of disease and tissue healing.
Gingipains have also been implicated in other diseases including Alzheimer’s disease, diabetes and cardiovascular disease.
Denteric is backed by an exceptional industry team.
